ERBB2 and breast carcinoma: This study aimed to analyze and compare the clinical and histopathological features of HER2-positive breast carcinomas across three subgroups: Group 1: Triple-positive (ER+/PR+/HER2+), Group 2:ER-positive only (ER+/PR-/HER2+), and Group 3: HER2-enriched (ER-/PR-/HER2+).<h4>Methods</h4>This was a single-institution, retrospective, cross-sectional study conducted over 42 months (January 2021-June 2024) at a tertiary care center comprising of 117 HER2-positive breast carcinoma cases.